Physician profile
Bryan A Walker
NPI 1144727959
$1,844.23
in general payments reported to CMS, 2019-2025
10 companies · $851 in 2025
The $851 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $73.76 · 2024: $919 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771 · Education: $73.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.11 |
| Education | $73.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $368.97 | 2023-2025 | Dalvance, Avycaz |
| Gilead Sciences, INC. | $366.20 | 2024-2025 | Biktarvy |
| Insmed, INC. | $285.16 | 2023-2025 | Arikayce, Brinsupri |
| Cumberland Pharmaceuticals, INC. | $208.53 | 2024-2025 | Vibativ |
| Merck Sharp & Dohme LLC | $196.02 | 2024-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $161.28 | 2024-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $103.32 | 2024-2025 | Xacduro, Zevtera, Xerava |
| Melinta Therapeutics, LLC | $80.33 | 2024-2025 | Rezzayo, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $43.72 | 2024-2025 | Nuzyra |
| Astellas Pharma US INC | $30.70 | 2025 | Cresemba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.